Endostatin – a potential biomarker for early prediction of preeclampsia
Preeclampsia is characterized by persistent high blood pressure and signs of liver or kidney damage that can affect pregnant women usually in the second half of pregnancy. It can also occur in women after the baby is delivered, mostly within 48 hours. Preelampsia occurs in around 2-8% of all pregnancies worldwide and is considered as a major cause of maternal and fetal mortality (1,2). It is responsible for over 70 000 maternal deaths and 500 000 fetal deaths worldwide every year (2). The cause of preeclampsia is still under debate and the clinical symptoms appear late during pregnancy (3). Early diagnosis is essential to prevent morbidity and mortality that is associated with preeclampsia (4).
Endostatin – a potential biomarker for early prediction of preeclampsia
Endostatin is one of the most potent inhibitors of angiogenesis as it specifically inhibits the proliferation and migration of endothelial cells. Endostatin is a degradation product of collagen XVIII, a protein of the extracellular matrix (ECM) which is expressed in the basement membranes. Endostatin is a stable analyte that can reliably be measured in human blood and urine samples.
Biochemical markers may be useful to predict preeclampsia early, prior to the onset of clinical signs. A recent study explored the potential use of the protein biomarker Endostatin for the early prediction of preeclampsia (5).
BIOMEDICA human ENDOSTATIN ELISA │BI-20742
- RELIABLE – validated according to FDA/ICH/EMEA guidelines
- FLEXIBLE – only ELISA that can measure human Endostatin in serum, plasma and urine
- OPTIMIZED for clinical samples – wide dynamic range
- TRUSTED – cited and sample values provided
- EFFICIENT – 20µl sample/well; results in 4.5 hours
BIOMEDICA mouse/rat ENDOSTATIN ELISA │BI-20742MR
- Fully validated for pre-clinical research (click here)
- Control included
Example of a BIOMEDICA ELISA assay kit
Literature
- Preeclampsia diagnosis and management. Best Pract Res Clin Anaesthesiol. Overton E, Tobes D, Lee A. 2022 May;36(1):107-121. doi: 10.1016/j.bpa.2022.02.003. Epub 2022 Feb 10. PMID: 35659948.
- Preeclampsia: Pathophysiology, Challenges, and Perspectives. Rana S, Lemoine E, Granger JP, Karumanchi SA. Circ Res. 2019 Mar 29;124(7):1094-1112. doi: 10.1161/CIRCRESAHA.118.313276. Erratum in: Circ Res. 2020 Jan 3;126(1):e8. PMID: 30920918.
- The placenta and preeclampsia: villain or victim? Melchiorre K, Giorgione V, Thilaganathan B. Am J Obstet Gynecol. 2022 Feb;226(2S):S954-S962. doi: 10.1016/j.ajog.2020.10.024. Epub 2021 Mar 24. PMID: 33771361.
- Early Detection of Preeclampsia Using Circulating Small non-coding RNA. Yoffe L, Gilam A, Yaron O, Polsky A, Farberov L, Syngelaki A, Nicolaides K, Hod M, Shomron N. Sci Rep. 2018 Feb 21;8(1):3401. doi: 10.1038/s41598-018-21604-6. PMID: 29467498; PMCID: PMC5821867.
- Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia. Alshannag F, Zaki RMM, Hemida E, ElBakry MMM, Noureldeen AFH. ACS Omega. 2023 Nov 1;8(45):42776-42786. doi: 10.1021/acsomega.3c05586. PMID: 38024766; PMCID: PMC10652833.
Citations
- Endostatin Is an Independent Risk Factor of Graft Loss after Kidney Transplant. Chu C, Hasan AA, Gaballa MMS, Zeng S, Xiong Y, Elitok S, Krämer BK, Hocher B. Am J Nephrol. 2020;51(5):373-380. doi: 10.1159/000507824. Epub 2020 Apr 22. PMID: 32320989.
- Validation of an enzyme-linked immunosorbent assay (ELISA) for quantification of endostatin levels in mice as a biomarker of developing glomerulonephritis. Wallwitz J, Aigner P, Gadermaier E, Bauer E, Casanova E, Bauer A, Stoiber D. PLoS One. 2019 Aug 12;14(8):e0220935. doi: 10.1371/journal.pone.0220935. PMID: 31404120; PMCID: PMC6690585.
- Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. Zobel EH, Theilade S, von Scholten BJ, Persson F, Tarnow L, Lajer M, Hansen TW, Rossing P. Diabetes Care. 2017 Mar;40(3):e32-e33. doi: 10.2337/dc16-2428. Epub 2017 Jan 6. PMID: 28062524.
- Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Gezer M, Taş A, Eyileten T, Guler AK, Aydin İ, Oguz Y, Tarim K, Covic A, Yilmaz MI. Eur J Intern Med. 2016 Sep;33:81-7. doi: 10.1016/j.ejim.2016.06.033. Epub 2016 Jul 7. PMID: 27394925.